Chemistry:LPH-48

From HandWiki

LPH-48 is a selective serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of alcoholism.[1][2][3] Its route of administration has not been specified.[1]

The drug acts as a selective agonist of the serotonin 5-HT2A receptor.[1][2][3] It is said to be an analogue of LPH-5 with similar characteristics but with faster metabolism and a shorter duration of action.[3] LPH-5 is a highly selective serotonin 5-HT2A receptor agonist that is under development for major depressive disorder and has shown antidepressant-like effects in animals.[4][5][6]

LPH-48 is under development by Lophora.[1][2] As of May 2024, it is in preclinical research for alcoholism.[1][2] The chemical structure of LPH-48 does not yet seem to have been disclosed.[1] However, Lophora has patented selective serotonin 5-HT2A receptor agonists for treatment of depression[7] and the company is said to have patent protection for LPH-48.[1] Additionally, the structure of its close analogue LPH-5 is known and this compound is a phenylpiperidine derivative.[4]

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "LPH 48". 22 May 2024. https://adisinsight.springer.com/drugs/800078258. "LPH 48 is a ligand therapeutic which has a similar pharmacological profile as psilocybin with superior selectivity and shorter duration, being developed by [...]" 
  2. 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on LPH-48 with Synapse". 19 September 2024. https://synapse.patsnap.com/drug/753954d9107b4522aa9b1a0e9d360016. 
  3. 3.0 3.1 3.2 Lophora (31 May 2024). "Lophora Submits Clinical Trial Authorisation (CTA) Application to the French Medicines Agency (ANSM) for Lead CNS Drug LPH-5". https://danskbiotek.dk/wp-content/uploads/2024/06/Press-Release.pdf. "About LPH-48: LPH-48 is a shorter acting direct analog of LPH-5 with similar optimized characteristics and safety profile, but with a shorter duration of action. LPH-48 is designed as a fast-follower that shows significantly faster metabolism, indicating a shorter duration of action in man. LPH-48 is a representative of the same proprietary compound class as LPH-5 and is therefore endowed with the same optimized characteristics including favorable drug-like properties and a safe pharmacological profile." 
  4. 4.0 4.1 "Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists". Journal of Medicinal Chemistry 67 (9): 7224–7244. May 2024. doi:10.1021/acs.jmedchem.4c00082. PMID 38648420. 
  5. "LPH 5". 7 March 2023. https://adisinsight.springer.com/drugs/800068514. 
  6. Jensen AA, Cecchi CR, Hibicke M, Bach AH, Kaadt E, Marcher-Rorsted E, Nichols CD, Elfving B, Kristensen JL (22 April 2024). "The selective 5-HT2Areceptor agonist LPH-5 induces persistent and robust antidepressant-like effects in rodents". bioRxiv 10.1101/2024.04.19.590212.
  7. Kristensen JL, Jensen AA, Märcher-Rørsted E, Leth-Petersen S, "5-HT2A agonists for use in treatment of depression", WO patent 2021/089824, published 14 May 2021